UroGen Pharma (URGN) Share-based Compensation Growth (3y) (2020 - 2026)
UroGen Pharma (URGN) Share-based Compensation Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 244.08% |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | -50.27% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | UroGen Pharma | 2.04 Bn | 1.90 Bn | 46.82 Mn | 157.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.65% |
| Dec 31, 2025 | 9.75% |
| Sep 30, 2025 | 7.45% |
| Jun 30, 2025 | 86.46% |
| Mar 31, 2025 | 1.34% |
| Dec 31, 2024 | -14.89% |
| Sep 30, 2024 | -14.15% |
| Jun 30, 2024 | -16.18% |
| Mar 31, 2024 | -23.66% |
| Dec 31, 2023 | -26.30% |
| Sep 30, 2023 | -30.98% |
| Jun 30, 2023 | -32.17% |
| Mar 31, 2023 | -33.05% |
| Dec 31, 2022 | 38.05% |
| Sep 30, 2022 | -30.42% |
| Jun 30, 2022 | -26.85% |
| Mar 31, 2022 | -26.57% |
| Dec 31, 2021 | -15.49% |
| Sep 30, 2021 | -16.62% |
| Jun 30, 2021 | -7.78% |